🏛️ Verified NIH Record • Updated 2025-05-01

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (NCT03144648)

Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: International Agency for Research on Cancer

🩺 Plain-English Summary (8th-Grade Level)

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.

Who can join: Review the eligibility criteria below.

Location: Barretos Cancer Hospital — Barretos

Age range: 20 Years to 45 Years

🧪 Interventions in This Study

  • lifestyle (OTHER)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (13 Sites)

  • Barretos Cancer Hospital — Barretos,
  • INC — Santiago, Independencia
  • Hso-Crsco — Santiago, Peñalolén
  • FALP — Santiago, Providencia
  • Grupo Infección y Cáncer. Universidad de Antioquia — Medellín, Antioquia
  • International Hospital of Colombia — Bucaramanga, Bucaramanga
  • Facultad de Medicina, Universidad del Norte — Barranquilla,
  • Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia — Bucaramanga,
  • SENOSAMA foundation — Bucaramanga,
  • Instituto de Oncología HematoOncologos — Cali,
  • Public Health University of Narino — Pasto,
  • Agencia Costarricense de Investigaciones Biomédicas (ACIB) — San José, Provincia de San José
  • Instituto Nacional de Salud Pública (INSP) — Cuernavaca, Morelos

📞 Contact the Study Coordinator

Phone: +33 472738485

Email: rinaldis@iarc.who.int

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗